1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

(Shutterstock)

While the results represent small patient numbers, Telix Pharmaceuticals has encouraging early Phase II data for TLX101 (131 I-iodofalan) in patients with recurrent high-grade gliomas, including glioblastoma (GBM), which likely warrants further study.

Key Takeaways
  • Telix announced Phase II data for a handful of patients, showing an overall survival increase among patients with high-grade gliomas, including glioblastoma.

The Melbourne, Australia-based firm on 15 April announced results from eight patients in the single-arm, investigator-initiated IPAX-Linz trial of external...

More from Anticancer

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.